Crossject

Update in progress

ALCJ.PA (Paris)

Company RatingNeutral
SectorHealthcare
IndustryMedical Instruments & Supplies

Crossject S.A. is a Dijon, France-based company that develops needle-free injection systems. It markets ZENEO, a pre-filled, single-use auto-injector. Its pipeline includes Midazolam, Naloxone, Terbutaline, Epinephrine, Sumatriptan, Hydrocortisone and Methotrexate for various medical uses, plus ZEPIZURE for seizure emergencies. The company was founded in 2001.

Company score

Sentiment: 0.34; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.14; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.04; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.19; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive